score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		SC_9021	SC_9021-Tumor	
Putatively Actionable	Clinical trial			Copy Number	BRCA2	Deletion				0.0	0.0		Putatively Actionable	Olaparib	PARP inhibition	Targeted therapy	Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.	Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708.	https://doi.org/10.1056/NEJMoa1506859													0				BRCA2 Deletion	1.0	SC_9021	SC_9021-Tumor	
Putatively Actionable	Clinical evidence			Copy Number	EGFR	Amplification				0.0	0.0		Putatively Actionable	Gefitinib	EGFR inhibition	Targeted therapy	Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.	Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37.	https://doi.org/10.1200/JCO.2005.01.0793													0				EGFR Amplification	1.0	SC_9021	SC_9021-Tumor	
Putatively Actionable	Inferential		Clinical evidence	Copy Number	CDKN2C	Deletion				0.0	0.0		Putatively Actionable	Palbociclib	CDK4/6 inhibition	Targeted therapy	Palbociclib is predicted to have antitumor effects in multiple myeloma patients with del(1p) resulting in loss of CDKN2C.	Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100-113.	https://doi.org/10.1038/nrclinonc.2016.122								Putatively Actionable	0.0	Either hemizygous or homozygous CDKN2C loss, identified by FISH, resulted in worse overall survival relative to wild type in a study of 515 multiple myeloma patients.	"Leone, Paola E., et al. ""Deletions of CDKN2C in multiple myeloma: biological and clinical implications."" Clinical Cancer Research 14.19 (2008): 6033-6041."	https://doi.org/10.1158/1078-0432.CCR-08-0347	0				CDKN2C Deletion	0.0	SC_9021	SC_9021-Tumor	
Putatively Actionable			Guideline	Copy Number	TP53	Deletion				0.0	0.0																Putatively Actionable	0.0	Deletion of 17p13 leads to LoH of TP53 and is considered a high-risk feature of multiple myeloma.	National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf	0				TP53 Deletion		SC_9021	SC_9021-Tumor	
Putatively Actionable			Guideline	Copy Number	RB1	Deletion				0.0	0.0																Putatively Actionable	0.0	Deletion of chromosome 13 seems to have an amplifying effect on cell cycle gene expression and is reported to be associated with short event-free survival (EFS) and overall survival (OS). This copy loss event results in haploinsufficiency of RB1 and other genes mapped to chromosome 13.	National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf	0				RB1 Deletion		SC_9021	SC_9021-Tumor	
Putatively Actionable			Clinical evidence	Copy Number	MYC	Amplification				0.0	0.0																Putatively Actionable	0.0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13.	https://doi.org/10.1007/s00401-011-0923-y	0				MYC Amplification		SC_9021	SC_9021-Tumor	
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 3	version 2	0.343						Investigate Actionability	Platinum	Platinum-based chemotherapy	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683													0				COSMIC Signature (version 2) 3 (34%)		SC_9021		
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						SC_9021		
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.V484fs	0.5165	91.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	0.0	0.0	0.0	BRCA2 p.V484fs (Frameshift)	0.0	SC_9021	SC_9021-Tumor	SC_9021-Normal
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.N290K	0.3251	443.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823						0	20.0	0.0	0.9266	ESR1 p.N290K (Missense)		SC_9021	SC_9021-Tumor	SC_9021-Normal
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)		SC_9021		
Biologically Relevant				Mutational Signature	COSMIC Signature 6	version 2	0.286																									0				COSMIC Signature (version 2) 6 (29%)		SC_9021		
